半夏泻心方及配伍药组含药血清抑制人胃癌BGC-823细胞增殖的实验研究  

Experimental study of Banxia Xiexin Prescription and druggroup in a prescription on control BGC-823 cell multiplication of human gastric cancer

作　　者：王萍[1] 李娟[1] 刘喜平[1] 李德兴[2] 高波[2] 邱桐 

机构地区：[1]甘肃中医学院,甘肃兰州730000 [2]甘肃省医学科学研究院,甘肃兰州730000

出　　处：《甘肃中医学院学报》2005年第5期14-17,共4页Journal of Gansu College of Traditional Chinese Medicine

基　　金：甘肃省教育厅基金资助项目(01B-32)

摘　　要：目的:研究半夏泻心方及其配伍药组对体外人胃癌BGC 823细胞增殖的影响。方法:采用血清药理学方法和MTT法及台盼兰染色法观察半夏泻心方及其配伍药组对体外人胃癌BGC 823细胞的敏感性及生长抑制作用。结果:辛苦组对人胃癌BGC 823细胞的生长抑制作用最强,显著高于辛开组、苦降组、辛甘组、苦甘组、甘补组(P<0.05)。结论:半夏泻心方中对BGC 823细胞增殖起主要抑制作用的药组为辛开、苦降的配伍形式。辛开、苦降配伍后(辛苦)有显著的协同增效趋势,而其他配伍药群可能存在拮抗作用。提示辛开苦降法可能是中医药防治胃癌的治则治法之一。Objective： To study the effect of Banxia Xiexin Prescription and drug-group in a prescription to BGC-823 cell multiplication of human gastric cancer out body. Methods： Observed the sensitivity and growth inhibitory effect of Banxia Xiexin Prescription and drug-group in a prescription to BGC-823 cell out body of human gastric cancer. Results： The growth inhibitory effect of Xinku group was strongest, and prominently higher than Xinkai, Kujiang, Xingan, Kugan and Ganbu group（ P 〈 0.05 ）. Conclusion ： Xinkai and Kujiang drug-group have main inhibitory effect to BGC-823 cell multiplication. It is positive cooperative during the compatibility of Xinkai and Xinjiang . However, it is antagonistic during others compatibility. It suggested that the method of Xinkai Kujiang is importent for cure and prevent of gastric cancer.

关 键 词：半夏泻心方 人胃癌BGC-823细胞 配伍 生长抑制 

分 类 号：R285.5[医药卫生—中药学]